Clinical Trial Update: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update for Retatrutide (LY3437943) in adults with obesity and cardiovascular disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Obesity

Drugs mentioned

• Retatrutide (retatrutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Cardiovascular Diseases | Phase 3 | Status: COMPLETED